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ABSTRACT
Aberrant ocular angiogenesis can underpin vision loss in leading causes of 
blindness, including neovascular age-related macular degeneration and proliferative 
diabetic retinopathy. Current pharmacological interventions require repeated invasive 
administrations, may lack efficacy and are associated with poor patient compliance and 
tachyphylaxis. Vitamin D has de novo anti-angiogenic properties. Here, our aim was to 
validate the ocular anti-angiogenic activity of biologically active vitamin D, calcitriol, and 
selected vitamin D analogue, 22-oxacalcitriol. Calcitriol induced a significant reduction 
in ex vivo mouse choroidal fragment sprouting. Viability studies in a human RPE cell line 
suggested non-calcemic vitamin D analogues including 22-oxacalcitriol have less off-
target anti-proliferative activity compared to calcitriol and other analogues. Thereafter, 
the anti-angiogenic activity of 22-oxacalcitriol was demonstrated in an ex vivo mouse 
choroidal fragment sprouting assay. In zebrafish larvae, 22-oxacalcitriol was found to be 
anti-angiogenic, inducing a dose-dependent reduction in choriocapillaris development. 
Subcutaneously administered calcitriol failed to attenuate mouse retinal vasculature 
development. However, calcitriol and 22-oxacalcitriol administered intraperitoneally, 
significantly attenuated lesion volume in the laser-induced choroidal neovascularisation 
mouse model. In summary, calcitriol and 22-oxacalcitriol attenuate ex vivo and in vivo 
choroidal vasculature angiogenesis. Therefore, vitamin D may have potential as an 
interventional treatment for ophthalmic neovascular indications.
InTRoduCTIon
Pathological neovascularisation of ocular blood 
vessels can promote vision loss in leading causes of 
blindness including neovascular age-related macular 
degeneration (nAMD) and proliferative diabetic retino-
pathy. Worldwide, 8.7% of blindness results from 
AMD. nAMD accounts for only 10% of AMD cases 
but greater than 80% of poor visual acuity cases [1-4]. 
Rapid vision loss in nAMD is driven by pathological 
choroidal vasculature angiogenesis. This pathological 
vasculature can be deficient in tight junctions, leak 
plasma or blood, cause scarring, project through the 
Bruch’s membrane, cause retinal pigmented epithelium 
(RPE) detachment and disrupt normal perfusion of the 
retina [5-7]. Worldwide 382 million people suffer from 
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diabetes, approximately 35% of whom develop diabetic 
retinopathy, making this the leading cause of blindness in 
the working age population [8]. Severe vision loss is a 
consequence of macular oedema and sprouting of poorly 
formed retinal vessels into the vitreous [8]. This retinal 
neovascularisation can result in haemorrhaging and retinal 
detachment [9].
Endogenous pro-angiogenic factors including 
vascular endothelial growth factor (VEGF), angiopoietins 
(ang-1, ang-2), platelet-derived growth factors (PDGF-A, 
PDGF-B) and transforming growth factor (TGF-β), plus 
their cognate receptors, promote normal vasculature 
development [6]. After development, a tightly regulated 
balance of pro- and anti-angiogenic factors maintain the 
mature quiescent vasculature. Pathological insults such 
as hypoxia can disrupt this equilibrium and promote 
neovascularisation [10, 11]. VEGF is a pivotal regulator 
of ocular and tumour angiogenesis, clinically evident 
from the success of anti-VEGF targeting therapies. 
Ranibizumab (Lucentis®), bevacizumab (Avastin®) and 
aflibercept (Eylea®) are utilised in the treatment of ocular 
neovascularisation [12]. These anti-VEGF therapies 
cause vessel regression and improve visual function 
[3]. Despite representing the standard of care, several 
treatment limitations exist. Firstly, with molecular 
weights between 50-149 kDa, current interventions 
require administration by intravitreal injection [13]. This 
places a burden both on patients and clinicians which 
can result in inadequate dosing, exemplified by the 
CATT/IVAN trial, where an average of 4-5 treatments 
were administered compared to the recommended 7-8 
[7]. Secondly, repeated administrations are required. 
Aflibercept has the greatest intravitreal half-life of the 
anti-VEGF therapies yet treatments are required every 2 
months [3, 14]. In addition, continuous long-term anti-
VEGF therapy is required, and cessation of treatment can 
result in reoccurrence of neovascularisation [15].Thirdly, 
anti-VEGF therapies are associated with a severe 
economic burden, with aflibercept costing approximately 
€1,000 per injection [16]. Finally, anti-VEGF therapy 
can lack efficacy in non-responsive populations and 
tachyphylaxis can occur. A non-responsive population of 
45% is reported with bevacizumab [17]. Tachyphylaxis 
is postulated to be a consequence of compensatory VEGF 
upregulation or generation of neutralising antibodies 
[14]. These limitations highlight the need to identify and 
develop safe, efficacious, cost effective anti-angiogenics 
with a less invasive route of administration.
Vitamin D is a fat-soluble steroid hormone with 
pleiotropic health implications. Recognised as having 
pro-differentiative, anti-proliferative, immunomodulatory, 
pro-apoptotic and anti-angiogenic properties; vitamin 
D is under examination for malignant, cardiovascular, 
cognitive, metabolic, infectious and autoimmune 
disorders [18-20]. Vitamin D has the potential to prevent 
and/or treat cancer and a proposed mechanism is through 
inhibition of angiogenesis required for tumour growth 
[21]. Interestingly, the vitamin D receptor (VDR) is 
expressed in the cornea, lens, ciliary body, RPE, ganglion 
cell layer and photoreceptors, supporting ocular functions 
[22]. In 2017, we reported the biologically active form 
of vitamin D, calcitriol, and diverse VDR agonists 
including vitamin D2 analogues, vitamin D3 analogues 
and a pro-hormone to attenuate in vivo ocular vasculature 
development in zebrafish  [23]. Further interrogation of the
anti-angiogenic activity was needed in ocular mammalian 
models to assess the therapeutic potential of vitamin D.
Here, we examined the anti-angiogenic activity of 
calcitriol and 22-oxacalcitriol in in vitro, ex vivo or in 
vivo vasculature systems. Calcitriol and 22-oxacalcitriol 
significantly inhibit ex vivo mouse choroidal sprou-
ting angiogenesis, yet in a simpler, non-ocular in 
vitro cord formation assay, anti-angiogenic activity 
was not identified. With increased model complexity 
calcitriol and 22-oxacalcitriol again induced anti-
angiogenic responses, showing reduced developmental 
angiogenesis in a zebrafish larval model and/or attenuated 
neovascularisation in a pathological mouse model 
which recapitulates features of nAMD. Drug safety 
was assessed through animal weight monitoring, and 
22-oxacalcitriol presented with a safer profile compared 
to calcitriol. Here, our studies support further pre-clinical 
investigations into non-calcemic vitamin D analogue, 
22-oxacalcitriol, for the treatment or prevention of 
choroidal neovascularisation.
RESuLTS
Calcitriol attenuates mouse ex vivo choroid-RPE 
fragment sprouting angiogenesis
Previously, we demonstrated calcitriol and seven other 
VDR agonists to inhibit ocular vasculature development 
in zebrafish larvae [23]. To identify the most active anti-
angiogenic VDR agonist in mammalian models, the cord 
formation assay, a late stage in vitro angiogenesis model, 
was performed. Human dermal-derived microvascular 
endothelial cells, HMEC-1 cells, were seeded in a matrix and 
cultured with 10 µM calcitriol, 22-oxacalcitriol, tacalcitol 
or vehicle control and cord formation quantified after 
16 h. The Angiogenesis Analyzer for ImageJ was utilised 
for automatic unbiased measurement of cord formation 
properties. Surprisingly, VDR agonist-treated HMEC-1 
cells exhibited no significant difference in cord formation 
compared to vehicle controls (Supplementary Figure 1A-
1B). Cord formation properties are influenced by cell 
type (primary or immortalised), derivation (human or 
non-human) and tissue origin [24]. With ocular selective 
anti-angiogenic activity previously identified in zebrafish 
larvae, cord formation was also investigated in human 
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retinal-derived microvascular endothelial cells (HREC). 
HREC cells were seeded in a matrix and cultured with 
10 µM calcitriol for 16 h. Again, no significant cord 
formation difference was identified between vehicle 
control and calcitriol treated HREC cells (Supplementary 
Figure 1C-1D).
To investigate the anti-angiogenic activity of 
calcitriol in a more physiologically relevant model, the ex 
vivo mouse choroidal sprouting angiogenesis assay was 
employed (Figure 1A). This system is multicellular in 
nature and accounts for micro-environmental cues which 
support angiogenesis [25]. Calcitriol treatments between 
5-10 µM significantly (p<0.001) reduced choroidal 
sprouting area by up to 93% compared to vehicle control. 
No significant difference in sprouting was identified 
with 1 µM calcitriol treatments (Figure 1B-1D). Calcein 
staining confirmed explant and sprout viability after 1-10 
µM treatments (Figure 1D).
Calcitriol attenuates RPE cell viability, while 
non-calcemic vitamin d3 analogues show a 
greater RPE cell safety profile
Pro-apoptotic and anti-proliferative properties of 
calcitriol are known [26]. Such actions on endothelial 
cells could underpin the anti-angiogenic mechanism of 
calcitriol. However, induction of apoptosis is undesirable 
in neighbouring cells such as the RPE. Thus, we sought 
to identify VDR agonists with negligible effects on RPE 
cell viability. VDR agonist-induced changes in ARPE-19 
cell number were determined by the surrogate measure 
of metabolic activity, quantified using the MTT assay. 
Calcitriol was tolerated over 24 h in ARPE-19 cells, with 
no significant change in cell viability with concentrations 
≤20 µM (Figure 2A). However, treatments with ≥10 µM 
calcitriol for 48 h significantly reduced ARPE-19 cell 
viability in a concentration-dependent manner, 10 µM 
(p≤0.05), 15 µM (p≤0.01) and 20 µM (p≤0.001) (Figure 
2B). Cell viability in response to a range of VDR agonist 
treatments were subsequently investigated in ARPE-19 
cells, over 96 h. Vitamin D2 analogue, doxercalciferol, 
reduced ARPE-19 cell viability (~42%) with 10 µM 
treatment (p≤0.01) (Figure 2C). Vitamin D2 analogue, 
paricalcitol, had no significant effect on ARPE-19 cell 
viability with treatments ≤10 µM (Figure 2D). Vitamin D3 
analogues, tacalcitol and calcipotriol, induced a significant 
reduction (~42 and 29%, respectively) in ARPE-19 cell 
viability with concentrations ≥5 µM (Figure 2E-F). Non-
calcemic vitamin D3 analogues were better tolerated. 
No significant change in ARPE-19 cell viability was 
identified with 22-oxacalcitriol or EB 1089 treatments ≤10 
µM (Figure 2G-H). Therefore, non-calcemic vitamin D3 
analogue, 22-oxacalcitriol, was selected for further 
investigation. Notably, further safety studies investigating 
the effects of non-calcemic vitamin D3 analogues in 
vivo are required, as a trend of reduced viability in vitro, 
although not significant, was demonstrated here. Finally, 
vitamin D3  pro-hormone, calcifediol, significantly 
attenuated ARPE-19 cell viability by up to 45% with 
concentrations ≥5 µM (p≤0.001) (Figure 2I).
non-calcemic vitamin d3 analogue 
22-oxacalcitriol inhibits mouse ex vivo choroidal 
sprouting angiogenesis
To investigate the anti-angiogenic activity 
of 22-oxacalcitriol, the ex vivo choroidal sprouting 
angiogenesis assay was performed. 10 µM 22-oxacalcitriol 
significantly attenuated mouse ex vivo choroid-RPE 
fragment sprouting angiogenesis by up to 42% (p≤0.05) 
(Figure 3A-3C). In addition, calcein staining confirmed 
explant and sprout viability after treatment (Figure 3C).
non-calcemic vitamin d3 analogue 
22-oxacalcitriol inhibits zebrafish 
choriocapillaris development
In zebrafish, the choriocapillaris starts developing 
by 24 hours post fertilisation (hpf) and becomes a perfused 
vascular network by 72 hpf. We treated zebrafish with 
ascending concentrations of 22-oxacalcitriol, between 24 
and 72 hpf, and evaluated the effects on choriocapillaris 
development (Figure 4A). Using the number of interstitial 
pillars (ISPs) as a measure of angiogenic activity, the 
development of the choriocapillaris was markedly 
inhibited by 22-oxacalcitriol in a concentration-dependent 
manner. While 0.1 µM did not lead to reduced ISP 
formation compared to controls, treatment with 1 or 10 
µM 22-oxacalcitriol led to a moderate reduction to 80.1% 
(±4.6) and 79.5% (±3.2) respectively of the ISPs found in 
control DMSO-treated eyes (Figure 4B-4C). Importantly, 
treatment with 22-oxacalcitriol distorted the characteristic 
lobular vascular pattern of the choriocapillaris 
(Figure 4C). These findings clearly indicate that 
22-oxacalcitriol inhibits choriocapillaris development in 
zebrafish.
Subcutaneous calcitriol treatment does not 
adversely affect adult mouse retinal structures or 
superficial retinal vasculature development
Prior to in vivo assessment of the anti-angiogenic 
activity of calcitriol, ocular safety was evaluated in 
adult C57BL/6J mice. Adult mice received a single 50 
ng subcutaneous calcitriol or vehicle control treatment, 
and retinal histology was investigated 7 days later. 
Vehicle controls and calcitriol treated mice presented 
with animal welfare scores comparable to un-injected 
mice, with mouse weight recorded daily (Figure 5B). On 
day 7, mice were euthanised, eyes enucleated, fixed and 
sectioned. Ultra-thin toluidine blue stained cross sections 
were investigated for the presence of pyknotic nuclei 
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Figure 1: Calcitriol attenuates mouse choroidal sprouting angiogenesis. (A) Mouse RPE-choroidal fragments were cultured 
in Matrigel® for 24 h and further cultured with indicated drug treatments for 6 days. On day 7, samples were fixed and sprouting area 
quantified from phase contrast images using ImageJ freehand tool. (B) Calcitriol 5-10 µM or 10 µM sunitinib positive control significantly 
attenuated choroidal sprouting angiogenesis. Graph shows mean percent sprouting area compared to vehicle control ± SEM; statistical 
analyses were performed using one-way ANOVA with Dunnett’s post hoc test, asterisk indicates ***p≤ 0.001 and n as indicated with up 
to 6 replicates per individual experiment. (C) Representative brightfield images of mouse choroidal sprouting after 7 days with indicated 
treatments. (d) Calcein stained representative images of mouse choroidal sprouting after 7 days with indicated treatments. Calcein staining 
of RPE-choroidal cultures confirms explant viability in vehicle and calcitriol treated explants. Scale bar represents 0.5 mm.
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and deviations in the highly organised cell lamination of 
the eye. Calcitriol treatments appeared well tolerated in 
mice, with no observable difference between vehicle and 
calcitriol treated retinal structures (Figure 5A).
Retinal vasculature development after birth in mice 
provides a unique opportunity to study developmental 
angiogenesis. Normal mouse retinal vasculature growth is 
well documented, and drugs can inhibit this growth [27-29]. 
Calcitriol attenuates zebrafish ocular developmental 
angiogenesis, therefore, we sought to investigate if 
this response translated to the mouse. To validate the 
model, the anti-angiogenic activity of positive control, 
rapamycin, was evaluated. C57BL/6J mouse pups were 
injected subcutaneously with 10 mg/kg rapamycin 
or vehicle control at postnatal day 1 (P1), welfare 
monitored daily and superficial retinal vasculature 
Figure 2: Vitamin d analogues attenuate ARPE-19 cell viability in a and concentration-dependent manner. (A-B)  
Serum starved ARPE-19 cells were cultured with 5-20 µM calcitriol for 24 h or 48 h and cell viability assessed by MTT assay. No significant 
difference in cell metabolic activity with 24 h calcitriol treatment was found. Calcitriol treatments (10-20 µM) for 48 h significantly reduced 
cell metabolic activity. (C-I) Serum starved ARPE-19 cells were cultured with 0.1-10 µM vitamin D2 analogues, vitamin D3 analogues, 
non-calcemic vitamin D3 analogues, vitamin D3 pro-hormone or vehicle control for 96 h and cell viability assessed by MTT assay. (C-D) 
Graphs show mean absorbance at 570 nm in response to vitamin D2 analogue treatment. (C) ARPE-19 cell viability was attenuated by 10 
µM doxercalciferol treatment. (D) No significant change in ARPE-19 cell viability was identified with 0.1-10 µM paricalcitol treatment. 
(E-F) Graphs show mean absorbance at 570 nm in response to vitamin D3 analogue treatment. (E) ARPE-19 cell viability was attenuated 
by 5-10 µM tacalcitol treatment. (F) ARPE-19 cell viability was attenuated by 5-10 µM calcipotriol treatment. (G-H) Graphs show mean 
absorbance at 570 nm in response to non-calcemic vitamin D3 analogue treatment. No significant change in ARPE-19 cell viability was 
identified with 0.1-10 µM 22-oxacalcitriol or EB 1089 treatment. (I) Graph show mean absorbance at 570 nm in response to vitamin D3 
pro-hormone, calcifediol. ARPE-19 cell viability was attenuated by 5-10 µM calcifediol treatment. Graphs show mean absorbance at 570 
nm ± SEM; statistical analysis by one-way ANOVA with Dunnett’s post-hoc test compared to vehicle control; asterisk signifies *p≤0.05, 
**p≤0.01 and ***p≤0.001 and group size is n = 3, with 4 replicates per n.
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development quantified at P4 (Supplementary Figure 2). 
No significant difference in mouse weight gain was 
identified between rapamycin and vehicle treated animals 
at P1 or P4 (Supplementary Figure 2A). Rapamycin 
treated mice presented with reduced superficial retinal 
vasculature area compared to vehicle control treated mice 
(Supplementary Figure 2B).
Initial studies showed a single calcitriol injection 
was insufficient to induce an anti-angiogenic response 
in this model. C57BL/6J mice pups were injected with 
3.75 ng subcutaneous calcitriol or vehicle control at P1, 
welfare monitored daily and superficial retinal vasculature 
development quantified (Supplementary Figure 3). No 
significant difference in superficial retinal vasculature area 
between calcitriol and vehicle control administered mice 
was identified at P4 (Supplementary Figure 3A & 3C) or 
P8 (Supplementary Figure 3B & 3C). A subsequent study 
performed subcutaneous calcitriol and vehicle control 
administration on P1, P3, P5 and P7. Mice pups presented 
with no welfare concerns and weight gain was comparable 
Figure 3: Vitamin d3 analogue attenuates mouse choroidal sprouting angiogenesis. Mouse RPE-choroidal fragments were 
cultured in Matrigel® for 24 h and further cultured with 10 μM 22-oxacalcitriol for 6 days. On day 7, samples were fixed and sprouting 
area quantified from phase contrast images using ImageJ freehand tool. (A) 22-oxacalcitriol and positive control sunitinib significantly 
attenuated choroidal sprouting angiogenesis. Graph showing mean percent sprouting area compared to vehicle control ± SEM; statistical 
analyses were performed using one-way ANOVA with Dunnett’s post hoc test; asterisk indicates *p≤0.05 and ***p≤0.001 and n = 3 with up 
to 6 replicates per individual experiment. (B) Representative brightfield images of mouse choroidal sprouting after 7 days with indicated 
treatments. (C) Representative calcein stained images of mouse choroidal sprouting after 7 days with indicated treatments. Calcein staining 
of RPE-choroidal cultures confirms explant viability in vehicle and 22-oxacalcitriol treated explants. Scale bar represents 0.5 mm.
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in vehicle control and calcitriol treated mice on P4 or P8 
(Figure 5C). Again, no significant difference in superficial 
retinal vasculature development between calcitriol and vehicle 
control treated mice was identified at P4 or P8 (Figure 5D-F).
22-oxacalcitriol inhibits mouse laser-induced 
choroidal neovascularisation without adverse 
effects
Previously calcitriol was reported to reduce 
retinal neovascularization in the mouse oxygen induced 
retinopathy (OIR) model of retinopathy of prematurity 
[30]. To extend upon this finding, we evaluated the effect of 
calcitriol in the laser-induced choroidal neovascularisation 
model (L-CNV). To visualize L-CNV and consequential 
vascular leakage, in vivo optical coherence tomography 
(OCT) imaging and fluorescein angiography (FA) were 
performed. Choroidal neovascularisation was inhibited 
by calcitriol (5 µg/kg/day) administered intraperitoneally 
(Figure 6A-C) and FA revealed vascular leakage of CNV 
lesions was reduced in calcitriol treated mice (Figure 
6B). However, calcitriol treatment had adverse effects on 
body weight (Figure 6D), perhaps due to hypercalcemia-
induced toxicity [31].
Therefore, we sought to evaluate the effect of 
22-oxacalcitriol, the non-calcemic bioactive analogue 
of calcitriol [32]. Notably, 22-oxacalcitriol (15 µg/kg/
day) administered intraperitoneally inhibited vascular 
leakage and CNV lesion volume assessed based on 
OCT images (Figure 7A-7C) without any adverse effect 
on body weight (Figure 7D). CNV was also assessed 
immunohistochemically by staining vasculature using 
agglutinin and isolectin GS-IB4. CNV lesion volumes 
were reduced by 25-30% upon 22-oxacalcitriol treatment 
(Figure 7F-H). QRT-PCR identified no significant 
difference between ocular Vegfa expression in mice treated 
with 22-oxacalcitriol or vehicle control (Figure 7E).
In summary, calcitriol and 22-oxacalcitriol 
attenuate mouse ex vivo choroidal vasculature sprouting, 
22-oxacalcitriol reduces choriocapillaris development in 
zebrafish larvae and both calcitriol and 22-oxacalcitriol 
inhibit choroidal neovascularisation in a mouse model 
with features of nAMD.
dISCuSSIon
The ocular vasculature systems support retinal 
development and visual function. Pathological ocular 
Figure 4: 22-oxacalcitriol attenuates choriocapillaris development in zebrafish larvae. (A) Tg(Fli1a:EGFP)y1 transgenic 
zebrafish larvae were treated with vehicle control or 22-oxacalcitriol between 24-72 hpf. (B) Graph showing number of ISPs as a measure 
of the extent of active vascular growth. Statistical analyses were performed using t-test; asterisk indicates **p≤0.01 and ***p≤0.001 and 
n = 2, N = 20. ns, non-significant. (C) Representative GFP images of choriocapillaris development in zebrafish larvae treated with vehicle 
control or 0.1-10 µM 22-oxacalcitriol treatment. Arrowheads indicate ISPs.
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neovascularisation is a hallmark in numerous diseases 
causing vision loss, including nAMD. Anti-angiogenics 
have revolutionised nAMD treatment, yet their long-
term safety profiles remain controversial and they require 
frequent intravitreal injection due to their molecular 
weights greater than 50 kDa [33, 34]. Here, we investigated 
the anti-angiogenic activity and safety of agonists 
targeting the VDR, in zebrafish larvae, human cell cultures 
and murine models. We report four significant findings. 
First, we demonstrate the ex vivo ocular anti-angiogenic 
activity of calcitriol and 22-oxacalcitriol in a physiological 
mouse model of angiogenesis. Second, 22-oxacalcitriol 
exerts ocular anti-angiogenic activity in a zebrafish model 
of choroidal vasculature development. Third, calcitriol 
and 22-oxacalcitriol attenuate neovascularisation in an in 
vivo pathological mouse model with features of nAMD. 
Figure 5: no ocular morphological defects were identified in mice treated with calcitriol and calcitriol treatment on 
alternating days does not attenuate superficial retinal vasculature development in C57BL/6J mice. (A) Toluidine blue 
stained ocular cross sections 7 days after vehicle or 50 ng calcitriol treatment show an absence of gross morphological defects and the 
presence of normal retinal lamination in ocular sections. RPE; retinal pigmented epithelium, OS; outer segment, IS; inner segment, ONL; 
outer nuclear layer, INL; inner nuclear layer, GCL; ganglion cell layer. Scale bar represents 0.5 mm. (B) Change in mouse body weight 
over 7 days was monitored as an indication of animal welfare. Graph shows change in body weight (g) ± SEM (n = 3) in response to vehicle 
control or 50 ng calcitriol treatment. (C-F) C57BL/6J mice at P1, P3, P5 and P7 received a s.c. injection of 3.75 ng calcitriol or vehicle 
control, welfare was monitored daily and superficial retinal vasculature development quantified at P4 or P8. (C) Change in mouse body 
weight between P1-4 or P1-8 was calculated, graph shows increase in body weight (g) from P1, ± SEM. No significant difference in body 
weight between 3.75 ng calcitriol and vehicle injected mice was identified at P4 or P8. (D) Superficial retinal vasculature area compared to 
retina area was calculated at P4 and P8. Scatter graph shows no significant difference between superficial retinal vasculature development 
at P4 or P8 between mouse pups treated with vehicle control or calcitriol. (E-F) Isolectin B4-Alexa Fluor 594 stained retinal flat-mount 
image representations show no difference between superficial retinal vasculature development at P4 or P8 between mouse pups treated with 
vehicle control or 3.75 ng calcitriol. Scale bar represents 500 µm and 1 mm, left and right panels, respectively.
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Finally, we show 22-oxacalcitriol, a vitamin D agonist 
not associated with hypercalcemia, to present with an 
improved safety profile compared to calcitriol in human 
RPE cells and mice. Together this supports the potential of 
vitamin D agonists, particularly 22-oxacalcitriol, as anti-
angiogenic agents for the treatment or prevention of ocular 
angiogenic disorders.
A combination of pathological changes to the 
photoreceptors, RPE, Bruch’s membrane and chor-
oid underpin visual impairment in nAMD. Therefore, 
Figure 6: Effect of calcitriol on choroidal neovascularisation. (A) CNV was induced by laser on day 0 and calcitriol delivered 
i.p. with a 5 days on/2 days off treatment regime. OCT, fundus and/or fluorescein angiography (FA) images were acquired on day 7 and/or 
14. (B) Representative OCT, fundus and FA images on day 14. GCL: ganglion cell layer, ONL: outer nuclear layer, RPE: retinal pigment 
epithelium. Plane of OCT images shown as a red line on brightfield fundus images. The horizontal black line in the FA images is inserted by 
the imaging software at the time of image capture; it shows the position of the OCT guide beam. Scale bars = 100 µm. (C) Quantification 
of the laser-induced CNV lesion volume calculated as an ellipsoid from OCT data, showing reduction in CNV lesions with calcitriol 
treatment on both day 7 and day 14. Calcitriol was delivered i.p. 5 µg/kg. Vehicle was almond oil. ***p=0.0002, Unpaired t-test (two tailed) 
with Welch’s correction, Mean ± SEM, n = 6-7 eyes. (d) Effects of calcitriol treatment on body weight. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001, two-way repeated-measures ANOVA with Holm-Sidak post hoc tests. Mean ± SEM, n = 6 animals.
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modelling such a complex disease in vitro can be 
challenging. The ex vivo choroidal sprouting angiogenesis 
model is multi-cellular, comprising of RPE cells, 
endothelial cells, macrophages and pericytes [25]. The 
choriocapillaris is the vasculature located immediately 
posterior to the RPE and highly sensitive to VEGF-A 
signalling during development and in pathologies such as 
AMD [1]. In initial studies, calcitriol attenuated ex vivo 
choroidal sprouting angiogenesis. This anti-angiogenic 
response is consistent with previous studies wherein 
Figure 7: Effect of 22-oxacalcitriol on choroidal neovascularisation. (A) CNV was induced by laser on day 0 and 15 µg/
kg 22-oxacalcitriol delivered i.p. daily. Vehicle was 0.1% ethanol-PBS. OCT, fundus and/or FA images were acquired on day 7 and 14. 
(B) Representative OCT, fundus and FA images on day 14. GCL: ganglion cell layer, ONL: outer nuclear layer, RPE: retinal pigment 
epithelium. Plane of OCT images shown as a red line on brightfield fundus images. Scale bars = 100 µm. (C) Quantification of the laser-
induced CNV lesion volume calculated as an ellipsoid from OCT data, showing reduction in CNV lesions with 22-oxacalcitriol treatment 
on both day 7 and day 14; day 14 data shown. ***p=0.0003, Unpaired t-test (two tailed) with Welch’s correction, Mean ± SEM, n = 7-8 
eyes. (d) Effects of 22-oxacalcitriol treatment on body weight. ns, non-significant, two-way repeated-measures ANOVA. Mean ± SEM, 
n = 6 animals. (E) Vegfa mRNA expression in the mouse eye was quantified after daily 22-oxacalcitriol or vehicle control for 14 days. 
Vegfa expression was consistent in vehicle control and 22-oxacalcitriol treated eyes. (F) Representative images from confocal microscopy 
of agglutinin and GS-IB4 stained CNV lesions 14 days post L-CNV. Scale bars = 100 μm. (G-H) Quantification of CNV lesion volume 
using Z-stack confocal images. *p<0.03, Unpaired t-test (two tailed) with Welch’s correction, Mean ± SEM, n = 7 eyes.
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calcitriol inhibits angiogenesis in a chick chorioallantoic 
membrane (CAM) model [35], an OIR model [30] 
and a transgenic mouse model of retinoblastoma [35]. 
Interestingly, here calcitriol did not inhibit in vitro cord 
formation in human dermal- or retinal-derived endothelial 
cells. This is contrary to previous findings which 
demonstrated calcitriol to inhibit mouse retinal endothelial 
cell capillary network formation on a basement membrane 
[30]. Interestingly, Bao et al. reported calcitriol to exert no 
effect on HUVEC cord formation, yet attenuated HUVEC 
cord formation when stimulated with prostate cancer cell 
conditioned medium [36]. These differences suggest that 
the anti-angiogenic activity of calcitriol is context- or 
environmental-dependent. As the choroidal explant assay 
employed here is multi-cellular in nature, it is plausible 
that anti-angiogenic responses are not directly induced by 
the endothelial cells, but instead through regulation from 
neighbouring cells (e.g. pericytes).
Calcitriol treatment induces oedema and impairs 
visual function in zebrafish larvae [23]. Therefore, 
the safety profile of calcitriol was assessed here in 
a mammalian system. In mice, calcitriol treatment 
was well-tolerated in developing pups with no 
ocular morphological welfare concerns or weight 
loss at selected dose. We hypothesised that in vivo 
calcitriol would stall development of the mouse retinal 
vasculature, correlating with previous observations in 
zebrafish larvae [23]. However, mouse retinal vascular 
plexus development at P4 or P8 was not attenuated by 
0.00375 μg calcitriol subcutaneously administered as 
a single dose or repeatedly on alternating days. The 
lack of efficacy could be a consequence of suboptimal 
dosing or short drug half-life (t½) of a few hours [37]. 
Alternatively, lack of anti-angiogenic activity could 
result from poor distribution to the eye, suboptimal 
vehicle selection or the early developmental status of 
the retinal vasculature. Calcitriol in vivo was previously 
reported to inhibit retinal neovascularization in a 
pathological OIR model of retinopathy of prematurity 
at a concentration of 5 μg/kg via intraperitoneal 
administration daily from P12 to P17 [30]. 
Subsequently, we hypothesised that calcitriol may 
exert an anti-angiogenic effect in vivo on the choroidal 
vasculature, consistent with our data in the ex vivo 
choroidal explants. Significantly, 5 µg/kg calcitriol 
administered intraperitoneally daily attenuated L-CNV 
in adult mice. However, the short calcitriol t½ suggests 
that frequent administration is required for chronic 
conditions [37]. Of further concern, the calcitriol-
treated arm in the L-CNV study presented with reduced 
body weight, a response also reported by Albert et al. 
in OIR studies [30]. Weight loss in calcitriol treated 
animals is likely a consequence of hypercalcemia.
Vitamin D regulates calcium mobilisation, therefore 
high-dose vitamin D treatment can induce hypercalcemia. 
VDR agonists including 22-oxacalcitriol were developed to 
reduce calcemic responses. 22-oxacalcitriol is a calcitriol 
analogue with an oxygen substituted for carbon at position 
22, and is approved for the treatment of psoriasis due to its 
therapeutic activity and reduced calcemic responses [38]. 
Interestingly, 22-oxacalcitriol inhibits CAM angiogenesis 
in a dose-dependent manner [39]. Here calcitriol decreased 
ARPE-19 cell viability, a result not observed with 
22-oxacalcitriol. Differing responses induced by vitamin D 
and analogues could be the result of altered protein 
binding, metabolism, receptor affinity, dimerization and 
co-regulator recruitment [38]. 22-oxacalcitriol is reported 
to have reduced vitamin D-binding protein affinity, up to 
500 times lower than calcitriol [40].
22-oxacalcitriol attenuates zebrafish hyaloid 
vasculature development, a lens associated system which 
metamorphs into a retina-associated vasculature system 
[23, 41]. Here, 22-oxacalcitriol attenuated both ex vivo 
mouse microvascular sprouting in choroidal explants and 
choroidal vasculature development in zebrafish larvae. 
Thus, our revised hypothesis was that 22-oxacalcitriol can 
exert an anti-angiogenic effect on the choroidal vasculature 
in vivo without adverse effects linked to hypercalcemia. 
Our novel findings demonstrate that 22-oxacalcitriol 
exerts significant anti-angiogenic activity in the mouse 
L-CNV model. Importantly, weight loss did not occur 
in the 22-oxacalcitriol treatment arms. An advantage of 
22-oxacalcitriol as a treatment for ocular disorders is, as a 
small molecule, vitamin D has the potential to be delivered 
orally. However, future studies will need to investigate 
the in vivo ocular pharmacokinetics and anti-angiogenic 
efficacy with oral administration.
Vitamin D traditionally mediates its effects through 
the VDR, a nuclear receptor expressed diversely throughout 
the body which regulates the transcription of hundreds of 
genes [38]. The anti-angiogenic effects of vitamin D appear 
VDR-dependent. First, knockout (KO) of the VDR affects 
tumour vasculature integrity, resulting in vessel enlargement 
and reduced pericyte coverage [42]. Second, increased 
expression of pro-angiogenic factors including VEGF have 
been identified in tumours from VDR KO mice [42]. Third, 
calcitriol attenuates oxygen-induced neovascularisation 
in mice, a response reduced in VDR KO mice [43]. We 
previously reported calcitriol treatments to regulate VEGF 
expression in the developing eye [23]. However, here in 
the L-CNV model, ocular Vegfa expression was not altered 
by 22-oxacalcitriol. This is in line with Albert et al. who 
found ocular VEGF protein expression to be comparable in 
calcitriol and vehicle control treated mice in the OIR model 
of ocular neovascularisation [30]. Angiogenesis is driven by 
an array of factors. Indeed, vitamin D regulates a plethora 
of other angiogenic factors including HIF1α, IL-8, TGF-β, 
bone morphogenetic protein-2A, endothelin 1, cysteine-
rich angiogenic inducer 6, midkine, MMP-2 and MMP-9 
[36, 44, 45]. Thus, additional studies are needed to elucidate 
the anti-angiogenic mechanism and VEGF dependency of 
responses induced by vitamin D in an ocular setting.
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In summary, we present original findings on the 
anti-angiogenic efficacy of VDR agonists in the eye 
using an evolutionarily diverse range of in vivo and ex 
vivo models. Notably, in a mouse model of pathological 
choroidal neovascularisation, 22-oxacalcitriol is well-
tolerated and significantly reduces the size of vascular 
lesions. This drug represents a promising therapeutic or 
preventative treatment for ocular angiogenic disorders 
associated with choroidal vasculopathies.
MATERIALS And METHodS
Ethical statement and approvals
Approval for the use of post-mortem mouse tissue 
for research purposes was granted by the UCD Animal 
Research Ethics Committee (AREC), AREC-16-31-
Kennedy. Mouse developmental and safety studies were 
conducted with approval by the UCD AREC (AREC-
15-07-Kennedy) and the Health Products Regulatory 
Authority (AE18982/P064). Mouse L-CNV experiments 
followed the guidelines of the Association for Research 
in Vision and Ophthalmology Statement for the Use of 
Animals in Ophthalmic and Visual Research and were 
approved by the Indiana University School of Medicine 
Institutional Animal Care and Use Committee. Zebrafish 
choroidal angiogenesis studies were approved by the 
Linköping Animal Research Ethics Committee (N89/15). 
All experiments were performed in accordance with 
relevant guidelines and regulations.
Mouse choroidal sprouting angiogenesis assay
The mouse choroidal sprouting procedure was 
adapted from Shao et al. and performed as per Figure 
1A [25]. C57BL/6J mice aged between 6-12 weeks 
were euthanised by CO2 asphyxiation, eyes immediately 
enucleated and placed in ice cold Endothelial Cell Growth 
Medium (PromoCell). Eyes were cut along the pars planar, 
cornea removed, lens removed, and four incisions made 
facilitating flattening of the eyecup. The neural retina was 
removed from the RPE/choroid complex and six-eight 
1 x 1 mm RPE-choroid explants cut from each quadrant. 
Explants were transferred to 30 µl thawed Matrigel® (BD 
Biosciences) in a 24 well plate, uniformly orientated, 
incubated for 20 min at 37°C (5% CO2, 95% O2) and 
500 μl medium applied. Following 1 day of culturing, 
medium was exchanged, and vehicle control, calcitriol 
and 22-oxacalcitriol treatments applied with a final well 
volume of 500 μl. Treatments were replenished on day 
3-4. Culturing was ended on day 7 and explants were 
imaged immediately, calcein stained or fixed in 4% PFA 
overnight.
Calcein staining
Following 7 days of culturing, RPE-choroid explants 
were washed with phosphate-buffered saline (PBS) and 
300 μl of 8 µg/ml Calcein AM (Thermo Fisher Scientific) 
applied to each explant and incubated for 1 h at 37°C (5% 
CO2, 95% O2). Three PBS washes were performed, and 
explants imaged.
Image acquisition and sprouting area quantification
Brightfield images were acquired using Olympus 
SZX16 or Zeiss Axiovert 200 M microscopes with Cell^F 
or Zeiss Axiovision image analysis software. Sprouting 
area and explant area were manually quantified using 
ImageJ freehand tool and explant area subtracted from 
overall area. Statistical differences between vehicle- 
and drug-treated samples were determined by one-way 
ANOVA with Dunnett’s post-hoc test. Statistical analyses 
were performed with PRISM 5 software and significance 
accepted where P≤0.05.
ARPE-19 cell MTT viability assay
ARPE-19 cells were maintained in Dulbecco’s 
Modified Eagle’s Medium Nutrient Mixture F-12 (Sigma 
Aldrich) with 10% fetal bovine serum (FBS) (Gibco), 2 
mM L-glutamine (Gibco) and 100 units/ml penicillin-
streptomycin (Gibco). Briefly, 1.4 × 104 cells were applied 
per well of a 96 well plate and incubated at 37°C (5% 
CO2, 95% O2) overnight in complete medium. Complete 
medium was replaced with FBS-negative medium and 
plates incubated overnight at 37°C (5% CO2, 95% O2). 
FBS-negative medium was replaced with treatments in 
FBS-negative medium at indicated concentrations, with 4 
replicate wells per treatment and incubated at 37°C (5% 
CO2, 95% O2). At the desired treatment end-point 10 µl 
of 5 mg/ml MTT labelling Reagent (Roche) was applied 
per well and plates incubated at 37°C (5% CO2, 95% O2) 
for 2 h. 100 µl solubilisation solution (Roche) was applied 
per well and plates incubated at 37°C (5% CO2, 95% O2) 
for 4 h and absorbance read at 570 nm (microplate reader, 
mtx lab systems). Statistical differences between vehicle- 
and drug-treated samples were determined by one-way 
ANOVA with Dunnett’s post-hoc test. Statistical analyses 
were performed with PRISM 5 software and significance 
accepted where P≤0.05.
Choriocapillaris development assay in zebrafish
Fertilised Tg(Fli1a:EGFP)y1 transgenic zebrafish 
eggs were incubated in Phenylthiourea -containing E3-
medium for 24 h and then treated with 0.1% DMSO 
(vehicle control) or 22-oxacalcitriol (Cayman Chemicals) 
at 0.1, 1.0 or 10 µM for an additional 48 h. The larvae 
were then anesthetised with 0.04% MS-222 (Ethyl 
3-aminobenzoate methane sulfonic acid salt 98%, Sigma 
Aldrich) and fixed in 4% PFA (Sigma Aldrich) for 30 
min at room temperature. The eyes were removed and 
dissected using watchmakers’ forceps (Dumont #5) under 
a dissection microscope (Nikon SMZ 1500). The eyes 
were flat-mounted on glass slides in Vectashield mounting 
medium (H-1000 Vector laboratories) and imaged by 
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confocal microscopy (Zeiss, LSM 700). The number of 
ISPs were counted manually and used as a measure of the 
extent of active vascular growth.
Calcitriol tolerance study in adult mice: Weight and 
retina histology
Calcitriol (Selleckchem) was dissolved to 1 mg/
ml in ethanol and working dilutions to 1 µg/ml in PBS 
prepared. Male C57BL/6J mice between 3-6 months were 
subcutaneously (s.c.) administered 50 ng calcitriol or 
vehicle control and animal weight recorded daily over a 
7 day period.
On day 7, mice were euthanised by CO2 
asphyxiation, eyes enucleated, bisected and fixed with 
2.5%: 2% glutaraldehyde: PFA in 0.1 M Sorenson 
phosphate buffer (SPB) (pH 7.3). Fixed eyes were washed 
in 0.1 M SPB and transferred to 1% osmium tetroxide 
in 0.2 M SPB for 1 h at room temperature. Eyes were 
exposed to an ethanol gradient; 30%, 50%, 70%, 90% 
for 10 min each; 100% for 1 h and acetone for 30 min. 
Eyes were uniformly positioned within an Epon resin 
primed mould, mould levelled with Epon resin composed 
of agar 100 resin, dodecenyl succinic anhydride, methyl 
nadic anhydride and 2,4,6-tris (dimethylaminomethyl) 
(Agar Scientific) and incubated overnight at 50°C. Ultra-
thin ocular cross sections, 1 µm, were acquired using a 
diamond knife and Leica EM UC6 microtome. Sections 
were toluidine blue stained, cover-slipped (DPX mounting 
medium) and representative images acquired (Nikon 
Eclipse E80i Microscope, Canon camera). Mouse retina 
morphology between vehicle control and calcitriol treated 
samples were compared to identify deviations in retina 
cell organisation, retinal thickness and pyknotic nuclei 
presence.
Mouse model of retinal vasculature development
Experimental design followed Yagasaki et al [46]. 
Dams along with their pups were raised in standard light 
(12 h light and 12 h dark cycle) and standard air conditions 
for the duration of the study.
Calcitriol dosing
Calcitriol was prepared as previously reported [47]. 
Calcitriol (Selleckchem) was dissolved to 1 mg/ml in 
ethanol and working dilutions of 1 µg/ml in PBS were 
prepared. Calcitriol multiple injection study: Pups received 
a 3.75 ng calcitriol or vehicle control s.c. treatment on P1, 
P3, P5 and P7. The subcutaneous route was chosen due 
to a greater technical compatibility to administer drugs in 
postnatal pups. Animal welfare was monitored daily until 
P4 or P8. On P4 and P8, mouse pups were euthanised by 
cervical dislocation, eyes immediately enucleated and 
fixed with 4% PFA overnight at 4°C.
Retina flat-mounts
Fixed eyes were positioned on a made-for-purpose 
indented dental wax strip, in PBS under a dissecting 
microscope. The eye was gripped at the optic nerve 
with a Dumont #5 forceps and excess exterior muscle 
removed using a springbow microdissection scissors. The 
optic nerve was removed, the eye was pierced along the 
pars planar, the anterior eye removed using a springbow 
dissection scissors and lens removed. The remaining 
eyecup was transferred to a glass slide and 4 incisions 
made 2 mm from the site of the optic nerve with a no. 11 
scalpel blade dividing the retina into 4 quadrants. Using 
a no. 11 blade the periphery of the quadrants were cut, 
straightening the outer edge and preventing curling of 
the retina. Retinal flat-mounts were stored in perm/block 
buffer composed of PBS with 0.5% Triton-X100, 1% goat 
serum, and 0.1 mM CaCl2 (Sigma-Aldrich).
Isolectin staining
Isolectin staining was performed as previously 
reported [48]. Retina flat-mounts underwent 
permeabilisation with perm/block buffer overnight at 
4°C. Perm/block buffer was replaced with 20 µg/ml GS 
isolectin B4 (Thermo Fisher Scientific) in perm/block 
buffer and incubated overnight at 4°C. Flat-mounts 
underwent 8 perm/block buffer washes over 4 h at 37°C 
with 30 min interval changes. Flat-mounts were stained 
with Alexa-streptavidin-564 (ThermoFisher Scientific) 
diluted in perm/block buffer 1:500 overnight at 4°C. Flat-
mounts underwent 8 perm/block buffer washes over 4 h 
at 37°C with 30 min interval changes. Flat-mounts were 
stored in PBS with 0.1 mM CaCl2. Flat-mounts were 
transferred to a glass slide, the retina cover-slipped with 
Aqua-Poly mount (Polyscience Inc) and stored protected 
from light at 4°C.
Flat-mount image acquisition and retinal vasculature 
area quantification
Fluorescent images were acquired using a Zeiss 
AxioVert 200M fluorescent microscope, Andor IQ2 software 
with Andor montaging or Olympus SZX16 fluorescence 
microscope with Cell^F software. Retinal superficial 
vasculature development was expressed as vasculature area 
compared to total flat-mount area. Area measurements were 
performed using ImageJ software freehand tool.
Mouse model of laser-induced choroidal neovascu-
larisation
Wild-type female C57BL/6J mice, 6–8 weeks of 
age, were purchased from the Jackson Laboratory (Bar 
Harbor, ME), and housed under standard conditions [49]. 
Intraperitoneal injections (i.p.) of 60 mg/kg ketamine 
hydrochloride and 2.5 mg/kg xylazine mixture were used 
for anaesthesia, and isoflurane overdose for euthanasia. 
Body weights were determined daily. All analyses were 
performed by a masked investigator.
Calcitriol dosing
Calcitriol (1000 ng/ml in almond oil; Professional 
Compounding Centers of America, Houston, TX) was 
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purchased from Indiana School of Medicine Laboratory 
Animal Resource Center’s drug distribution center. Each 
mouse received once-daily i.p. injections of 5 µg/kg 
calcitriol or almond oil vehicle for 14 days (5 days on/2 
days off). The dose was determined based on published 
observations [30].
22-oxacalcitriol dosing
Pure crystalline solid 22-oxacalcitriol (Cayman 
Chemical, Ann Arbor, MI) was dissolved in ethanol as 
previously reported to yield a 2 µg/µl stock solution [50, 
51]. This stock solution was diluted in PBS to working 
solution, 2 µg/ml 22-oxacalcitriol in 0.1% ethanol-PBS 
on day of the injection. Each mouse in the treatment 
group received once-daily i.p. injections of 15 µg/kg 
22-oxacalcitriol or ethanol-PBS vehicle every day for 14 
days.
Laser-induced choroidal neovascularisation
The L-CNV mouse model was performed as 
previously described [52]. Briefly, both eyes of 6-8 week 
old C57BL/6J mice were dilated using tropicamide, and 
subjected to laser treatment using 50 µm spot size, 50 ms 
duration and 250 mV pulses of an ophthalmic argon green 
laser wavelength 532 nm, coupled to a slit lamp. Three 
laser burns per eye were created around the optic nerve 
at 12, 3 and 9 o’ clock positions. OCT was performed 
in L-CNV mice as described previously [52], on days 7 
and 14 post laser, using a Micron III intraocular imaging 
system (Phoenix Research Labs, Pleasanton, CA, USA). 
Briefly, eyes of anesthetised mice were dilated with 1% 
tropicamide solution (Alcon, Fort Worth, TX, USA) and 
lubricated with Gonak hypromellose ophthalmic solution 
(Akorn, Lake Forest, IL, USA). Horizontal and vertical 
OCT images were taken per lesion and L-CNV lesion 
volumes were obtained using the quantification method 
previously established [52, 53]. To assess vascular 
leakage, FA was performed on day 14 post L-CNV by 
i.p. injection of 50 μl of 25% fluorescein sodium (Fisher 
Scientific, Pittsburgh, PA, USA). Fundus images were 
taken using the Micron III system and Streampix software.
Choroidal flat-mounts
Mouse eyes were harvested on day 14 post L-CNV 
induction. The eyes were enucleated and fixed in 4% PFA 
in PBS for 1 h at 4°C. The anterior portion including lens 
and the retina were removed, then the posterior eyecups were 
dissected out and underwent further fixation in 4% PFA in 
PBS overnight. The fixed eye cups were washed in blocking 
buffer (0.3% Triton X-100, 5% bovine serum albumin (BSA) 
in PBS) for 2 h at 4°C. The eye cups were then stained for 
vasculature using the rhodamine-labeled Ricinus communis 
agglutinin I (Vector Labs, Burlingame, CA, USA) and 
Alexa Fluor 488 conjugated-Isolectin B4 from Griffonia 
simplicifolia (GS-IB4) (Molecular Probes, Thermo Fisher 
Scientific) at 1:250 dilution in buffer containing 0.3% Triton 
X-100, 0.5% BSA in PBS, overnight at 4°C. The posterior 
eyecups were washed three times with PBS and mounted 
in fluorescent mounting medium (VectaShield; Vector 
Laboratories, Inc.) and cover-slipped. Confocal imaging 
and analysis of L-CNV lesion volume were performed as 
previously described [53]. Treatments were compared by 
unpaired t-test (two tailed) with Welch’s correction, while 
mouse body weights were compared by two-way repeated-
measures ANOVA with Holm-Sidak post hoc tests using 
GraphPad Prism v. 6.
Mouse eye RnA extraction, cdnA synthesis and QRT-
PCR
Mouse eyes were harvested on day 14 post 
L-CNV induction, lens and cornea removed and eye 
stored in RNAlater. Total ocular RNA was extracted 
using mirVana™ miRNA Isolation Kit (Thermo Fisher 
Scientific) as per the manufacturer’s instructions. cDNA 
synthesis was carried out using VILO cDNA Synthesis 
Kit (Thermo Fisher Scientific) as per the manufacturer’s 
instructions. QRT-PCR reactions: 0.5 μl Taqman specific 
probe, 5 μl TaqMan Gene Expression Master Mix, 2.5 μl 
RNAse-free water and 2 μl cDNA template were made 
up on ice. QRT-PCR cycles were carried out with 
a QuantStudio 7 Flex Real-Time PCR System with 
QuantStudio™ Software and the following conditions 
applied: 50°C for 2 min, 95°C for 10 min, 95°C for 15 s 
with 40 repeats and 60°C for 1 min.
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